CION Ameerpet
Kidney Cancer · Types, Grades & Staging
Clear cell renal cell carcinoma — the commonest kidney cancer, explained
Your report says clear cell renal cell carcinoma — often written ccRCC, or simply clear cell kidney cancer. It is the commonest kidney cancer in adults, and the name is a description of how your cells looked down a microscope, not a statement about how the tumour will behave. This page stays with the subtype itself: where in the kidney it begins, why the cells look empty on a slide, what the VHL pathway has to do with it, how it sits beside the other kidney cancers, and what the grade and stage lines printed next to it actually mean.
- “Clear” is a laboratory description — The fat and glycogen inside these cells dissolve when the tissue is prepared for a slide, leaving the cytoplasm looking empty. It says nothing on its own about how fast the tumour grows.
- One pathway explains most of it — Loss of the VHL brake leaves the low-oxygen signal switched on, which pours out blood-vessel growth factors. That is why these tumours are so vascular and why they enhance brightly on a contrast CT.
- The subtype that immunotherapy was built around — For advanced clear cell disease, NCCN-guided systemic treatment starts from checkpoint blockade, alone or in combination. That therapy is delivered in-house by CION medical oncologists.
- Diagnosis in-house, kidney surgery coordinated — CT, MRI, ultrasound, biopsy, blood work, genetic counselling and systemic therapy are delivered in-house at CION. Kidney surgery and ablation are coordinated with specialist urology, uro-oncology and interventional radiology partners, where they may also be billed.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
From your nephron to your report
What “clear cell” actually means
Clear cell is a subtype of renal cell carcinoma, the family that most adult kidney cancers belong to — our page on renal cell carcinoma, the main kidney cancer covers that family as a whole. Our kidney cancer guide starts further back still, with symptoms and diagnosis. This page follows one word on your report to where it came from.
It begins in the filtering tubes, not the collecting system
Each kidney is built from around a million filtering units called nephrons. Clear cell renal cell carcinoma arises from the lining of the proximal tubule — the first stretch of tubing after blood has been filtered, where most of the water, salt and sugar the body wants to keep is pulled back in. That starting point matters, because a cancer that begins in the urine-collecting plumbing instead is a different disease altogether, with a different treatment path.
The cells stockpile fat and sugar
Proximal tubule cells work hard and handle a great deal of traffic. When they turn cancerous in this particular way, their metabolism shifts and they begin to store large amounts of lipid and glycogen inside the cell body. Under a microscope in a living state that cytoplasm would look full, not empty. Nothing has been lost from the cell — which is the first thing to understand before the name makes sense.
Slide processing washes the store away — hence “clear”
To be examined, tissue is fixed, dehydrated through a series of solvents, embedded, cut into very thin sections and stained. Those solvents dissolve fat and glycogen. What reaches the pathologist is a thin rim of membrane and a nucleus surrounded by an apparently empty space. The tumour is not hollow and it is not a fluid-filled cyst. “Clear cell” is a laboratory artefact that turned out to be such a reliable signature of one kind of kidney cancer that it became its name.
Behind the appearance sits the VHL brake
In most clear cell tumours the VHL gene, on the short arm of chromosome 3, has stopped working. Its normal job is to clear away HIF, the signal a cell raises when it is short of oxygen. With the brake gone, that signal stays switched on permanently, and the cell behaves as though it were suffocating even in a well-oxygenated kidney. In most people this fault is acquired inside the tumour and is not inherited.
A permanent distress signal builds a permanent blood supply
A cell that believes it is starving of oxygen does the logical thing: it calls for more blood. It releases vessel-growth factors, chiefly VEGF, and new vessels grow into the tumour. This is why clear cell renal cell carcinoma is one of the most vascular solid tumours there is, why it enhances so brightly when contrast is given during a CT, and why blood in the urine can appear early. The same biology is what modern treatment aims at.
The subtype is confirmed, then read with everything else
The pattern on a kidney-protocol contrast CT is suggestive, but the subtype is settled on tissue — from a needle core biopsy, or from the tumour once it has been removed — supported by immunostains where the appearance is ambiguous. Imaging, biopsy and blood work are delivered in-house at CION; kidney surgery is coordinated for you with specialist urology and uro-oncology partners, where it may also be billed. The subtype, grade and stage then go to a tumour board together, and the plan is built along NCCN lines. The route from there is set out on our kidney cancer treatment in Hyderabad page. Book a free consultation if you would like your report read this way.
Clear cell is a subtype, not a stage — and not a severity score.
Two people can both have clear cell renal cell carcinoma and be in entirely different situations, because the subtype only says which kind of cell the cancer came from. How far it has gone is the stage, and how abnormal the cells look is the grade. Those three lines are decided separately and are meant to be read together.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
The subtype is one line. Ask what the whole report says.
Our medical oncologists read the subtype, grade and stage together, arrange a specialist re-read of the slides where the finding is borderline, and tell you plainly what changes and what does not. Free first consultation, and no commitment to start treatment.
One family, several members
Clear cell RCC next to the other kidney cancers
Most of these are subtypes of renal cell carcinoma; two of them are not renal cell carcinoma at all. The reason the distinction is laboured on your report is that the subtype changes which systemic treatments are worth discussing, not just the label.
| Kidney cancer | What it is | How it differs from clear cell RCC |
|---|---|---|
| Clear cell RCC | The commonest adult kidney cancer, arising from the proximal tubule, usually with a lost VHL brake and a rich new blood supply. | — the reference point for this table. Highly vascular, bright on contrast CT, and the subtype in which checkpoint blockade and VEGF-targeted therapy are best established. |
| Papillary RCC | The next commonest renal cell subtype, growing in finger-like fronds. Reported as type 1 or type 2, which behave differently. | Driven by different pathways, so the VHL story does not apply. Often less vascular, which can make it look duller on a contrast scan, and its systemic options are chosen differently. |
| Chromophobe RCC | An uncommon renal cell subtype made of large pale cells with distinct outlines. | Generally the least inclined of the three common subtypes to spread. It is not routinely given a nuclear grade in the way clear cell tumours are, because the same grading system does not carry the same meaning. |
| Sarcomatoid or rhabdoid features | Not a subtype in its own right, but a change that can appear inside any of them, including clear cell. | Reported on a separate line because it sets the grade at its highest by definition and shifts the discussion towards systemic therapy earlier. |
| Collecting duct & medullary RCC | Rare cancers starting deeper in the kidney, in the collecting ducts or the medulla. | Behave aggressively and are managed along quite different lines. Medullary carcinoma in particular is linked to sickle cell trait, which clear cell RCC is not. |
| Urothelial carcinoma of the renal pelvis | A cancer of the lining of the urine-collecting chamber inside the kidney. | Not a renal cell carcinoma at all. It is closer to bladder cancer in behaviour and treatment, which is why the distinction is made carefully before any plan is set. |
| Wilms tumour | The kidney cancer of childhood, arising from embryonic kidney tissue. | A different disease in a different age group, managed by paediatric protocols. Adults are very rarely affected. |
| Renal sarcoma | A rare cancer of the connective tissue, blood vessels or capsule of the kidney rather than its filtering cells. | Sits outside the renal cell family entirely and follows sarcoma treatment principles, not kidney cancer ones. |
If your report gives a subtype you cannot find in this table, that is not a bad sign in itself — the classification of kidney tumours has been revised repeatedly and several uncommon entities now have names of their own. It is a fair question to put to your oncologist, and a good reason to have the report read line by line rather than word by word.
The lines beside it
What the rest of the report adds to “clear cell”
The subtype tells your team which disease they are treating. These are the lines that tell them where it has reached and how it is behaving — and each of them has a page of its own.
Grade
How abnormal the cells look
Clear cell tumours are given a nuclear grade from 1 to 4, based on how prominent the nucleolus is inside the cell nucleus and at what magnification it can be seen. Grade is decided independently of stage, and a small tumour can carry a high grade. What it means over time is set out on how grade affects kidney cancer prognosis.
Stage
How far it has reached
Stage comes from the TNM system: the tumour itself, the lymph nodes and whether there is spread elsewhere. Kidney cancer staging explained walks through how the categories are assigned, and tumour size and kidney cancer stage covers the size thresholds that move a tumour from one stage into the next.
Still in the kidney
Stage 1 and stage 2
These describe a tumour that has not grown beyond the kidney, separated by size. Most incidentally found clear cell tumours are picked up here, and the discussion turns on preserving as much kidney as possible. Read stage 1 kidney cancer and stage 2 kidney cancer for what each one means.
Beyond the kidney
Stage 3
Here the tumour has grown into the surrounding fat or a major vein, or has reached nearby lymph nodes, but not distant organs. Clear cell RCC has a particular tendency to grow along the renal vein, which is one of the things a staging scan looks for. Stage 3 kidney cancer explains what follows.
If it has spread
Stage 4 and metastatic disease
Spread to distant organs makes the disease stage 4, and systemic therapy leads from that point. Stage 4 kidney cancer covers what the stage means, and metastatic kidney cancer covers where clear cell RCC tends to travel and how each site is watched.
Systemic therapy
Why the subtype changes the drug class
Because clear cell tumours are vascular and visible to the immune system, advanced disease is treated from checkpoint blockade — PD-1 inhibition, sometimes with CTLA-4 inhibition, sometimes paired with a VEGF-targeted TKI, with mTOR inhibition held in reserve. Immunotherapy for advanced kidney cancer explains how the choice is made.
And after treatment. Clear cell renal cell carcinoma can return years later, which is why follow-up scanning continues well beyond the first year and why any new symptom is taken seriously rather than waited out. How recurrent kidney cancer is found sets out what surveillance looks for and when. Across all of this, imaging, biopsy, blood work, genetic counselling, radiation and systemic therapy are delivered in-house by CION, while kidney surgery, ablation and PET-CT are coordinated with specialist urology, uro-oncology and interventional radiology partners, where they may also be billed. The full route, with costs explained in writing before anything begins, is on our kidney cancer treatment in Hyderabad page.
Take the first step
Bring the report to someone who will read all of it
Every case at CION goes to a tumour board, not one doctor's opinion. If a line on your report is being over-read, we will say so.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Questions people ask about clear cell renal cell carcinoma
What is clear cell renal cell carcinoma?
Clear cell renal cell carcinoma, usually shortened to ccRCC or called clear cell kidney cancer, is the commonest form of kidney cancer in adults. It begins in the lining of the proximal tubule, the part of the nephron that does the first stage of filtering blood. The name describes appearance, not behaviour. When the tissue is prepared for a microscope slide, the fat and glycogen stored inside these cells dissolve away and leave the cytoplasm looking clear or washed out. It is treated as a distinct subtype because it has its own biology, its own look on a contrast scan and its own treatment options, which is why your report names it rather than simply saying kidney cancer.
Why is it called clear cell kidney cancer?
Purely because of what the cells look like on a stained slide. These tumour cells are loaded with lipid and glycogen, and the solvents used to prepare tissue for microscopy dissolve both. What is left is a thin rim of membrane around a space that appears clear. Nothing is actually missing from the cell while it is in the body. It is a laboratory description that stuck, and it does not mean the tumour is empty, hollow, fluid-filled or harmless. A fluid-filled kidney cyst is a completely different finding, described in a different way. If your report says clear cell, it is describing the microscope appearance of a solid tumour.
Does clear cell RCC respond to immunotherapy?
Clear cell renal cell carcinoma is one of the tumour types in which immune checkpoint blockade changed the standard of care, and NCCN guidance places immunotherapy-based combinations first for advanced disease. The reason is biological: these tumours are unusually visible to the immune system and unusually rich in new blood vessels. Treatment is therefore built around checkpoint inhibitors, most often PD-1 blockade, sometimes combined with CTLA-4 blockade and sometimes paired with a VEGF-targeted tyrosine kinase inhibitor. Which combination suits you depends on your stage, your IMDC risk group, your other illnesses and what your kidney function will tolerate. Systemic therapy of this kind is delivered in-house by CION medical oncologists.
Is clear cell RCC more aggressive than other kidney cancers?
Not as a rule, and the subtype name on its own does not tell you how a tumour will behave. Clear cell tumours cover the whole range, from small slow-growing lesions found by chance on a scan done for something else, to disease that has already spread by the time it is found. What predicts behaviour is the combination of stage, nuclear grade, tumour size and whether sarcomatoid or rhabdoid features are present, not the words clear cell. Compared with the other common subtypes it is more inclined to spread through the bloodstream, which is why staging scans are thorough. It is also the subtype that responds best to modern immunotherapy and VEGF-targeted treatment.
What does the VHL gene have to do with clear cell kidney cancer?
The VHL gene sits on the short arm of chromosome 3 and normally acts as a brake, clearing away a signal called HIF that cells use to announce they are short of oxygen. In most clear cell renal cell carcinomas that brake is lost, so HIF stays switched on even when oxygen is plentiful. The cell then behaves as though it were starved and pours out growth signals, including VEGF, which recruits new blood vessels. That is why clear cell tumours are so vascular, why they enhance brightly on a contrast CT, and why treatments aimed at the VEGF pathway work in this subtype. In most people the fault is acquired in the tumour alone and is not inherited.
Is clear cell RCC hereditary?
Usually not. The great majority of clear cell renal cell carcinomas arise from changes that happen inside kidney cells during life and are not passed on to children. A minority are linked to an inherited syndrome, of which von Hippel-Lindau disease is the best known, and those cases tend to announce themselves in a recognisable pattern: a diagnosis at an unusually young age, tumours in both kidneys, more than one tumour in the same kidney, or a family history of kidney cancer and related tumours. If any of that applies to you, genetic counselling and testing are worth arranging, and CION provides both in-house. It changes screening for your relatives, not only your own plan.
This page is general health information about one subtype of kidney cancer. It is not a diagnosis, and it cannot replace a specialist review of your own slides, scans and report. Only a doctor who has seen your pathology and examined you can say what a clear cell diagnosis means for you and which treatments apply. If you have a report you do not understand, please arrange a review rather than waiting — and tell your team straight away about new bone pain, breathlessness, unexplained weight loss or blood in the urine, because those symptoms change what is looked at next.